(-)-1-phenyl-2-propylaminopentane

(-)-1-phenyl-2-propylaminopentane ((-)PPAP) is a drug with an unusual effects profile. It can loosely be grouped with the antidepressant drug families, but its mechanism of action is quite different.^[1]

PPAP is classified as a catecholaminergic and serotonergic activity enhancer. This means that it stimulates the impulse propagation mediated transmitter release of the neurotransmitters synapse regardless of external input, while with PPAP the pattern of neurotransmitter release is not changed, but when the neuron would normally release neurotransmitter, a larger amount than normal is released.^[2]

Other drugs which produce this effect are the endogenous trace amines monoamine oxidase inhibitor, PPAP has no monoamine oxidase inhibitory activity, and produces only the activity enhancer effect.^[4]

References

1. ^ Knoll J, Knoll B, Torok Z, Timar J, Yasar S. The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant. Archives Internationales de Pharmacodynamie et de Therapie. 1992 Mar-Apr;316:5-29.
2. ^ Knoll J, Miklya I, Knoll B, Marko R, Kelemen K. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sciences. 1996;58(10):817-27.
3. ^ Knoll J, Miklya I, Knoll B, Marko R, Racz D. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Life Sciences. 1996;58(23):2101-14.
4. ^ Csaba G, Kovacs P, Pallinger E. Acute and delayed effect of (-) deprenyl and (-) 1-phenyl-2-propylaminopentane (PPAP) on the serotonin content of peritoneal cells (white blood cells and mast cells). Cell Biochemistry and Function. 2006 Jan-Feb;24(1):49-53.